Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

4.215 +0.015 (+0.36%)

Streaming Delayed Price Updated: 11:19 AM EDT, Mar 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	227,794
Open	4.220
Bid (Size)	4.210 (1,200)
Ask (Size)	4.220 (400)
Prev. Close	4.200
Today's Range	4.160 - 4.270
52wk Range	4.200 - 14.69
Shares Outstanding	68,196,526
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)

March 24, 2026

Via AB Newswire

Niagen Bioscience Increases Share Repurchase Program to $20 Million

March 19, 2026

From Niagen Bioscience, Inc

Via Business Wire

Performance

YTD	-32.6%	-32.6%
1 Month	-16.5%	-16.5%
3 Month	-36.0%	-36.0%
6 Month	-57.4%	-57.4%
1 Year	-38.9%	-38.9%

More News

Niagen Bioscience to Present at the 38th Annual ROTH Conference

March 18, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗

March 04, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

March 17, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

March 10, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience (NAGE) Earnings Transcript ↗

March 04, 2026

Via The Motley Fool

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

March 04, 2026

Via Chartmill

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

March 04, 2026

From Niagen Bioscience, Inc

Via Business Wire

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

Via FinancialNewsMedia

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

February 26, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

February 25, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

February 06, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

February 09, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

January 15, 2026

From Niagen Bioscience, Inc

Via Business Wire

Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science

January 29, 2026

From Equity Insider

Via GlobeNewswire

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast

December 22, 2025

From Niagen Bioscience, Inc

Via Business Wire

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

January 21, 2026

From USA News Group

Via GlobeNewswire

Niagen Bioscience Announces $10 Million Share Repurchase Program

November 06, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

November 13, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

November 04, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

November 12, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

October 06, 2025

From Niagen Bioscience, Inc

Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?

Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.

What exchange does Niagen Bioscience, Inc. - Common Stock trade on?

Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?

The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market

What is the current price of Niagen Bioscience, Inc. - Common Stock?

The current price of Niagen Bioscience, Inc. - Common Stock is 4.215

When was Niagen Bioscience, Inc. - Common Stock last traded?

The last trade of Niagen Bioscience, Inc. - Common Stock was at 03/30/26 11:19 AM ET

What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?

The market capitalization of Niagen Bioscience, Inc. - Common Stock is 287.45M

How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?

Niagen Bioscience, Inc. - Common Stock has 287M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.